Equity Analysis /

AU : Control Bionics - Successful entry into Japanese market

    Scott Power
    Scott Power

    Senior Analyst - Healthcare, Life Science & Technology

    28 April 2022
    Published by

    CBL posted its 3Q22 result which was in line with expectations. The company continues to progress its expansion into new geographies, with the successful entry into the Japanese market with distributor Double R&D and continued sales progression in Singapore. We make no changes to our forecasts and valuation and retain our Speculative Buy recommendation with a A$1.32 target price.